Law360, New York (March 01, 2011, 4:23 PM ET) -- Allergan Inc. revealed in a regulatory filing Tuesday it had been hit with two separate subpoenas by the U.S. Securities and Exchange Commission seeking further information about its affiliation with Acadia Pharmaceuticals Inc. and the sale of its securities.
In addition to the two SEC subpoenas, Allergan said in its 2010 annual report that it was subject to two Medicaid investigations from regulators in New York.
According to Allergan, the SEC first asked for documents related to its relationship with Acadia and the sale of Acadia...
Allergan's Acadia Securities Sales Spark SEC Subpoenas
To view the full article, take a free trial now.
